Immunoglobulin M Monoclonal Gammopathies of Undetermined Significance and Indolent Waldenström's Macroglobulinemia Recognize the Same Determinants of Evolution Into Symptomatic Lymphoid Disorders: Proposal for a Common Prognostic Scoring System
- 20 July 2005
- journal article
- hematologic malignancies
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 23 (21), 4662-4668
- https://doi.org/10.1200/jco.2005.06.147
Abstract
To evaluate the clinicohematologic variables at diagnosis that are prognostically related to neoplastic progression in patients with immunoglobulin M (IgM) monoclonal gammopathies of undetermined significance (MGUS), and indolent Waldenström's macroglobulinemia (IWM), and propose a scoring system to identify subsets of patients at different risk. We evaluated 217 patients with IgM MGUS and 201 with IWM (male-female ratio, 131:86 and 117:84; mean age, 63.7 and 63.6 years, respectively) diagnosed on the basis of serum monoclonal component (MC) levels and bone marrow lymphoplasmacytic infiltration degree. The variables selected by univariate analyses were multivariately investigated; on the basis of their individual relative hazards, a scoring system was devised to identify subsets of patients at different risk of evolution. After a median follow-up of 56.1 and 60.2 months, 15 of 217 MGUS and 45 of 201 IWM patients, respectively, required chemotherapy for symptomatic WM (13 and 36), non-Hodgkin's lymphoma (2 and 6) and amyloidosis (0 and 3). The median time to evolution (TTE) was not reached for MGUS and was 141.5 months for IWM. The variables adversely related to evolution were qualitatively the same in both groups: MC levels, Hb concentrations and sex. A scoring system based on these parameters identified three risk groups with highly significant differences in TTE in both groups (P < .0001). MGUS and IWM identify disease entities with different propensities for symptomatic neoplastic evolution. As both have the same prognostic determinants of progression, we propose a practical scoring system that, identifying different risks of malignant evolution, may allow an individualized clinical approach.This publication has 20 references indexed in Scilit:
- Clinical characteristics and factors predicting evolution of asymptomatic IgM monoclonal gammopathies and IgM-related disordersLeukemia, 2004
- Developing diagnostic criteria in Waldenstrom's macroglobulinemiaSeminars in Oncology, 2003
- Predictive variables for malignant transformation in 452 patients with asymptomatic IgM monoclonal gammopathySeminars in Oncology, 2003
- Smouldering Waldenstrom's macroglobulinemia: Factors predicting evolution to symptomatic diseaseSeminars in Oncology, 2003
- Asymptomatic Waldenstrom's macroglobulinemiaSeminars in Oncology, 2003
- A Long-Term Study of Prognosis in Monoclonal Gammopathy of Undetermined SignificanceThe New England Journal of Medicine, 2002
- Waldenström macroglobulinaemia: presenting features and outcome in a series with 217 casesBritish Journal of Haematology, 2001
- The Spectrum of IgM Monoclonal Gammopathy in 430 CasesMayo Clinic Proceedings, 1987
- Multiple myeloma or benign monoclonal gammopathy? A study of differential diagnostic criteria in 44 casesClinical Immunology and Immunopathology, 1978
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958